fluorouracil has been researched along with B16 Melanoma in 49 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether multiple low doses of 5-fluorouracil could repress myeloid derived suppressor cells in low frequency and, in turn, could enhance anti-tumor responses and promote a more prolonged survival in a murine melanoma model." | 7.81 | Multiple Low Doses of 5-Fluorouracil Diminishes Immunosuppression by Myeloid Derived Suppressor Cells in Murine Melanoma Model. ( Ajami, M; Ashourpour, M; Hadjati, J; Jadidi-Niaragh, F; Mirzaei, HR; Namdar, A; Rezaei, A, 2015) |
| "A mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft were used to assess the effect of DCA and capecitabine combined treatment." | 7.79 | DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft. ( Huang, WD; Shen, SY; Zheng, MF, 2013) |
| "A new delivery formulation (5FU-MS) of 5-fluorouracil (5FU), 5FU incorporated in microspheres composed of poly(glycolide-co-lactide) matrix, has been developed for the treatment of peritoneal carcinomatosis, and is designed to slowly release the incorporated 5FU for 3 weeks." | 7.69 | Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals. ( Fujita, T; Hagiwara, A; Imanishi, T; Muranishi, S; Ohgaki, M; Sakakura, C; Sawai, K; Takahashi, T; Tsujimoto, H; Yamamoto, A; Yamazaki, J, 1996) |
| "Using the model of B16 melanoma growing intraperitoneally in syngeneic C57BL/6 mice, we show that these GEM or 5-FU treatment regimens reduced MDSC in the peritoneal cavity of tumor-bearing mice." | 5.39 | Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. ( Felder, MA; Perez Horta, Z; Qu, X; Rakhmilevich, AL; Sondel, PM, 2013) |
| "Three mouse cancer cell lines [CT26 mouse colon cancer cells, B16 melanoma cells and Lewis lung carcinoma (LLC)], 5 human carcinoma cell lines (human esophageal squamous cell carcinoma cell lines TE8 and HEC46 and the human pancreatic carcinoma cell lines PK-9, AsPC-1 and SUIT-2) and 5 chemotherapeutic agents [mitoxantrone (MIT), mitomycin C(MMC), 5-fluorouracil (5FU), camptothecin (CPT-11) and cisplatin (CDDP)] that are frequently used in a clinical setting for cancer treatment were utilized to investigate the surface expression level of calreticulin and HLA class I after exposure to chemotherapeutic agents." | 3.81 | The key role of calreticulin in immunomodulation induced by chemotherapeutic agents. ( Hirano, S; Kuroda, A; Kuwatani, T; Kyogoku, N; Maki, T; Miyauchi, K; Shichinohe, T; Takeuchi, S; Tsuchikawa, T; Wada, M; Yamamura, Y, 2015) |
| "To assess whether multiple low doses of 5-fluorouracil could repress myeloid derived suppressor cells in low frequency and, in turn, could enhance anti-tumor responses and promote a more prolonged survival in a murine melanoma model." | 3.81 | Multiple Low Doses of 5-Fluorouracil Diminishes Immunosuppression by Myeloid Derived Suppressor Cells in Murine Melanoma Model. ( Ajami, M; Ashourpour, M; Hadjati, J; Jadidi-Niaragh, F; Mirzaei, HR; Namdar, A; Rezaei, A, 2015) |
| "A mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft were used to assess the effect of DCA and capecitabine combined treatment." | 3.79 | DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft. ( Huang, WD; Shen, SY; Zheng, MF, 2013) |
| "A new delivery formulation (5FU-MS) of 5-fluorouracil (5FU), 5FU incorporated in microspheres composed of poly(glycolide-co-lactide) matrix, has been developed for the treatment of peritoneal carcinomatosis, and is designed to slowly release the incorporated 5FU for 3 weeks." | 3.69 | Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals. ( Fujita, T; Hagiwara, A; Imanishi, T; Muranishi, S; Ohgaki, M; Sakakura, C; Sawai, K; Takahashi, T; Tsujimoto, H; Yamamoto, A; Yamazaki, J, 1996) |
| "61 cases of the gastric cancers have been treated with Replenishing Qi and Invigorating Spleen (RQIS) combined with chemotherapy." | 2.67 | [Clinical and experimental study in treating gastric cancer with replenishing qi and invigorating spleen oral liquid combined with chemotherapy]. ( Chen, CH; Sun, GZ; Wang, GM, 1994) |
| "Melanoma is a disease that need not be deadly." | 2.38 | The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening. ( Greene, MH, 1993) |
| " However, when administrated intratumorally, this effect can only be achieved in combination with dendritic cells (DCs) activation." | 1.62 | Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment. ( Dang, N; Lin, Y; Sprangers, B; Waer, M, 2021) |
| "5-Fluorouracil (5-FU) has been used as a chemotherapeutic drug for various types of cancer, although the development of resistance remains a major limitation for its use in clinical settings." | 1.42 | Anti-angiogenic effects of resveratrol in combination with 5-fluorouracil on B16 murine melanoma cells. ( Kim, YM; Koo, BS; Lee, SH; Park, SY, 2015) |
| "Using the model of B16 melanoma growing intraperitoneally in syngeneic C57BL/6 mice, we show that these GEM or 5-FU treatment regimens reduced MDSC in the peritoneal cavity of tumor-bearing mice." | 1.39 | Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. ( Felder, MA; Perez Horta, Z; Qu, X; Rakhmilevich, AL; Sondel, PM, 2013) |
| "or i." | 1.35 | Antitumor effect of combined treatment of mice with cytostatic agents and bacteriophage T4. ( Celka, M; Dabrowska, K; Górski, A; Kurzepa, A; Nevozhay, D; Opolski, A; Pozniak, G; Radzikowski, C; Switala-Jelen, K; Syper, D; Szczaurska-Nowak, K; Wietrzyk, J, 2009) |
| " Based on the findings, the antitumor effects of a selected retinoid either alone or in combination with cisplatin were also investigated in a preclinical mouse melanoma model." | 1.35 | Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. ( Chan, SY; Ho, PC; Liu, X, 2008) |
| "Finally, RhoB inhibits melanoma metastasis to the lung in a mouse model." | 1.32 | Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. ( Cheng, J; Djeu, JY; Jiang, K; Sebti, S; Sun, J; Wei, S, 2004) |
| "Hypoxia in tumors is associated with malignant progression, metastatic spread, and increased resistance to radiotherapy and chemotherapy." | 1.31 | Nitric oxide-mediated regulation of chemosensitivity in cancer cells. ( Adams, MA; Gofton, TE; Graham, CH; Matthews, NE; Maxwell, LR, 2001) |
| "Animals bearing established B16 melanoma or MB-49 bladder carcinoma were used to study the most effective scheduling of recombinant murine IL-12 (rmIL-12), along with systemic chemotherapy." | 1.30 | Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. ( Ara, G; Buxton, D; Leonard, J; Schaub, RG; Teicher, BA, 1997) |
| "Growth of B16 melanoma that had been subcutaneously implanted into the feet of C57 BL mice was inhibited by treatment with the combinations of 5-FU and HYP, of 5-FU and DP, and of 5-FU, HYP and DP as compared with the administration of 5-FU alone." | 1.28 | 5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole. ( Kusumoto, H; Maehara, Y; Masuda, H; Sakaguchi, Y; Sugimachi, K; Takahashi, I; Yoshida, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (12.24) | 18.7374 |
| 1990's | 12 (24.49) | 18.2507 |
| 2000's | 10 (20.41) | 29.6817 |
| 2010's | 20 (40.82) | 24.3611 |
| 2020's | 1 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Giorgi-Renault, S | 1 |
| Renault, J | 1 |
| Gebel-Servolles, P | 1 |
| Baron, M | 1 |
| Paoletti, C | 1 |
| Cros, S | 1 |
| Bissery, MC | 1 |
| Lavelle, F | 1 |
| Atassi, G | 1 |
| Fries, KM | 1 |
| Joswig, C | 1 |
| Borch, RF | 1 |
| Bussolari, JC | 1 |
| Ramesh, K | 1 |
| Stoeckler, JD | 1 |
| Chen, SF | 1 |
| Panzica, RP | 1 |
| Zhang, H | 3 |
| Zhu, P | 3 |
| Liu, J | 3 |
| Yang, X | 1 |
| Xu, S | 2 |
| Yao, H | 3 |
| Jiang, J | 3 |
| Ye, W | 3 |
| Wu, X | 3 |
| Xu, J | 3 |
| Lin, Y | 2 |
| Wang, Y | 1 |
| Dang, N | 1 |
| Waer, M | 1 |
| Sprangers, B | 1 |
| Khosravianfar, N | 1 |
| Hadjati, J | 2 |
| Namdar, A | 2 |
| Boghozian, R | 1 |
| Hafezi, M | 1 |
| Ashourpour, M | 2 |
| Kheshtchin, N | 1 |
| Banitalebi, M | 1 |
| Mirzaei, R | 1 |
| Razavi, SA | 1 |
| Yang, CJ | 2 |
| Chang, WW | 1 |
| Lin, ST | 1 |
| Chen, MC | 2 |
| Lee, CH | 2 |
| Kuo, CT | 1 |
| Wu, LH | 1 |
| Pangilinan, CR | 1 |
| Phacharapiyangkul, N | 1 |
| Liu, W | 1 |
| Chen, YH | 1 |
| Zhu, LF | 1 |
| Zheng, Y | 1 |
| Fan, J | 1 |
| Yao, Y | 1 |
| Ahmad, Z | 1 |
| Chang, MW | 1 |
| Zheng, MF | 1 |
| Shen, SY | 1 |
| Huang, WD | 1 |
| Qu, X | 1 |
| Felder, MA | 1 |
| Perez Horta, Z | 1 |
| Sondel, PM | 1 |
| Rakhmilevich, AL | 1 |
| Yamamura, Y | 1 |
| Tsuchikawa, T | 1 |
| Miyauchi, K | 1 |
| Takeuchi, S | 1 |
| Wada, M | 1 |
| Kuwatani, T | 1 |
| Kyogoku, N | 1 |
| Kuroda, A | 1 |
| Maki, T | 1 |
| Shichinohe, T | 1 |
| Hirano, S | 1 |
| Rosa, A | 1 |
| Nieddu, M | 1 |
| Piras, A | 1 |
| Atzeri, A | 1 |
| Putzu, D | 1 |
| Rescigno, A | 1 |
| Lee, SH | 1 |
| Koo, BS | 1 |
| Park, SY | 1 |
| Kim, YM | 1 |
| Otsubo, D | 1 |
| Yamashita, K | 1 |
| Fujita, M | 1 |
| Nishi, M | 1 |
| Kimura, Y | 1 |
| Hasegawa, H | 1 |
| Suzuki, S | 1 |
| Kakeji, Y | 1 |
| Tahmasebi, H | 1 |
| Khoshgard, K | 1 |
| Sazgarnia, A | 1 |
| Mostafaie, A | 1 |
| Eivazi, MT | 1 |
| Mirzaei, HR | 1 |
| Jadidi-Niaragh, F | 1 |
| Ajami, M | 1 |
| Rezaei, A | 1 |
| Kumari, S | 1 |
| Kondapi, AK | 1 |
| Szczaurska-Nowak, K | 1 |
| Dabrowska, K | 1 |
| Celka, M | 1 |
| Kurzepa, A | 1 |
| Nevozhay, D | 1 |
| Wietrzyk, J | 1 |
| Switala-Jelen, K | 1 |
| Syper, D | 1 |
| Pozniak, G | 1 |
| Opolski, A | 1 |
| Górski, A | 1 |
| Radzikowski, C | 1 |
| Matsumoto, K | 1 |
| Obara, N | 1 |
| Ema, M | 1 |
| Horie, M | 1 |
| Naka, A | 1 |
| Takahashi, S | 1 |
| Imagawa, S | 1 |
| Dubey, PK | 2 |
| Singodia, D | 2 |
| Vyas, SP | 2 |
| Schwartz, L | 1 |
| Abolhassani, M | 1 |
| Guais, A | 1 |
| Sanders, E | 1 |
| Steyaert, JM | 1 |
| Campion, F | 1 |
| Israël, M | 1 |
| Verma, RK | 1 |
| Kulcsár, G | 1 |
| Gaál, D | 1 |
| Kulcsár, PI | 1 |
| Schulcz, Á | 1 |
| Czömpöly, T | 1 |
| Wang, X | 1 |
| Lin, J | 1 |
| Zhang, X | 1 |
| Liu, Q | 1 |
| Xu, Q | 1 |
| Tan, RX | 1 |
| Guo, Z | 1 |
| KINSEY, DL | 1 |
| Critchley, RJ | 1 |
| Jezzard, S | 1 |
| Radford, KJ | 1 |
| Goussard, S | 1 |
| Lemoine, NR | 1 |
| Grillot-Courvalin, C | 1 |
| Vassaux, G | 1 |
| Jiang, K | 1 |
| Sun, J | 1 |
| Cheng, J | 1 |
| Djeu, JY | 1 |
| Wei, S | 1 |
| Sebti, S | 1 |
| Kang, WK | 1 |
| Park, EK | 1 |
| Lee, HS | 1 |
| Park, BY | 1 |
| Chang, JY | 1 |
| Kim, MY | 1 |
| Kang, HA | 1 |
| Kim, JY | 1 |
| Gupta, Y | 1 |
| Jain, A | 1 |
| Jain, P | 1 |
| Jain, SK | 1 |
| Choudhury, SA | 1 |
| Kauler, P | 1 |
| Devic, S | 1 |
| Chow, TY | 1 |
| Liu, X | 1 |
| Chan, SY | 1 |
| Ho, PC | 1 |
| Wang, GM | 1 |
| Chen, CH | 1 |
| Sun, GZ | 1 |
| Greene, MH | 1 |
| Ueda, H | 1 |
| Manda, T | 1 |
| Matsumoto, S | 1 |
| Mukumoto, S | 1 |
| Nishigaki, F | 1 |
| Kawamura, I | 1 |
| Shimomura, K | 1 |
| Hagiwara, A | 2 |
| Takahashi, T | 2 |
| Sawai, K | 1 |
| Sakakura, C | 2 |
| Tsujimoto, H | 1 |
| Imanishi, T | 1 |
| Ohgaki, M | 1 |
| Yamazaki, J | 1 |
| Muranishi, S | 2 |
| Yamamoto, A | 1 |
| Fujita, T | 1 |
| Chelladurai, M | 1 |
| Lobocki, CA | 1 |
| Sultani, M | 1 |
| Hanna, Y | 1 |
| Drelichman, A | 1 |
| Pieper, DR | 1 |
| McLaughlin, PW | 1 |
| Shirasu, M | 1 |
| Yamasaki, J | 1 |
| Togawa, T | 1 |
| Hyon, S | 1 |
| Ikada, Y | 1 |
| Viroonchatapan, E | 1 |
| Sato, H | 1 |
| Ueno, M | 1 |
| Adachi, I | 1 |
| Murata, J | 1 |
| Saiki, I | 1 |
| Tazawa, K | 1 |
| Horikoshi, I | 1 |
| Teicher, BA | 1 |
| Ara, G | 1 |
| Buxton, D | 1 |
| Leonard, J | 1 |
| Schaub, RG | 1 |
| Matthews, NE | 1 |
| Adams, MA | 1 |
| Maxwell, LR | 1 |
| Gofton, TE | 1 |
| Graham, CH | 1 |
| Maehara, Y | 1 |
| Sakaguchi, Y | 1 |
| Takahashi, I | 1 |
| Yoshida, M | 1 |
| Kusumoto, H | 1 |
| Masuda, H | 1 |
| Sugimachi, K | 1 |
| Rootman, J | 1 |
| Kumi, C | 1 |
| Bussanich, N | 1 |
| Damji, K | 1 |
| Gudauskas, G | 1 |
| Baumgart, J | 1 |
| Zhukovskaya, NV | 1 |
| Anisimov, VN | 1 |
| Olsen, KR | 1 |
| Blumenkranz, M | 1 |
| Hernandez, E | 1 |
| Hajek, A | 1 |
| Hartzer, M | 1 |
| Morrow, M | 1 |
| Wait, RB | 1 |
| Rosenthal, RA | 1 |
| Gamelli, RL | 1 |
| Gribel', NV | 1 |
| Pashinskiĭ, VG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Romidepsin Given on Days One, Three, and Five in Patients With Thyroid and Other Advanced Cancers[NCT00048334] | Phase 1 | 28 participants (Actual) | Interventional | 2002-10-26 | Completed | ||
| Phase I Study of Topical Romidepsin (Depsipeptide) in Early Stage Cutaneous T-Cell Lymphoma[NCT01445340] | Phase 1 | 6 participants (Actual) | Interventional | 2007-04-21 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and B16 Melanoma
| Article | Year |
|---|---|
The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education, and screening.
Topics: Animals; Anticarcinogenic Agents; Dysplastic Nevus Syndrome; Eflornithine; Fluorouracil; Humans; Mas | 1993 |
1 trial available for fluorouracil and B16 Melanoma
| Article | Year |
|---|---|
[Clinical and experimental study in treating gastric cancer with replenishing qi and invigorating spleen oral liquid combined with chemotherapy].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Therapy, Combi | 1994 |
47 other studies available for fluorouracil and B16 Melanoma
| Article | Year |
|---|---|
Heterocyclic quinones. 17. A new in vivo active antineoplastic drug: 6,7-bis(1-aziridinyl)-4-[[3-(N,N-dimethylamino)propyl]amino]-5,8- quinazolinedione.
Topics: Animals; Antineoplastic Agents; Aziridines; Breast Neoplasms; Cell Division; Cell Line; Drug Screeni | 1991 |
Synthesis and biological evaluation of 5-fluoro-2'-deoxyuridine phosphoramidate analogs.
Topics: Amides; Animals; Antineoplastic Agents; Floxuridine; Leukemia L1210; Magnetic Resonance Spectroscopy | 1995 |
Synthesis and biological evaluation of N4-substituted imidazo- and v-triazolo[4,5-d]pyridazine nucleosides.
Topics: Adenosine Deaminase Inhibitors; Animals; Antineoplastic Agents; Cattle; Humans; Leukemia L1210; Mela | 1993 |
Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Humans; Liver Neoplas | 2014 |
Synthesis, in vitro and in vivo antitumor activity of pyrazole-fused 23-hydroxybetulinic acid derivatives.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, | 2015 |
Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Drug Screening Assays, A | 2015 |
Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dendritic Cells; Female; | 2021 |
Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
Topics: Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Dendritic Cells; Female; Fluorouracil; Humans; | 2018 |
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane; Combined Modality T | 2018 |
Eicosapentaenoic acids enhance chemosensitivity through connexin 43 upregulation in murine melanoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Connexin 43; Dose-Respons | 2019 |
A novel core-shell nanofiber drug delivery system intended for the synergistic treatment of melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Chitosan; Drug Delivery Systems; Drug | 2019 |
DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2013 |
Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
Topics: Adjuvants, Immunologic; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothera | 2013 |
The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Calreticulin; Camptothecin; Carcinoma, | 2015 |
Maltese mushroom (Cynomorium coccineum L.) as source of oil with potential anticancer activity.
Topics: Agaricales; Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Colonic N | 2015 |
Anti-angiogenic effects of resveratrol in combination with 5-fluorouracil on B16 murine melanoma cells.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; An | 2015 |
Early-phase Treatment by Low-dose 5-Fluorouracil or Primary Tumor Resection Inhibits MDSC-mediated Lung Metastasis Formation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Fluorouracil; Lung Neoplasms; Melanoma, Ex | 2015 |
Enhancing the efficiency of 5-aminolevulinic acid-mediated photodynamic therapy using 5-fluorouracil on human melanoma cells.
Topics: Aminolevulinic Acid; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Synergism; Drug Therapy | 2016 |
Multiple Low Doses of 5-Fluorouracil Diminishes Immunosuppression by Myeloid Derived Suppressor Cells in Murine Melanoma Model.
Topics: Animals; CD8-Positive T-Lymphocytes; Clinical Protocols; Disease Models, Animal; Drug Dosage Calcula | 2015 |
Lactoferrin nanoparticle mediated targeted delivery of 5-fluorouracil for enhanced therapeutic efficacy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Carriers; Drug Liberation; Drug | 2017 |
Antitumor effect of combined treatment of mice with cytostatic agents and bacteriophage T4.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; | 2009 |
Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model.
Topics: Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Lewis Lung; Cell Proliferation; Enzy | 2009 |
Liposomes modified with YIGSR peptide for tumor targeting.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Drug Delivery Systems; Endothelium, Vascular; Fluor | 2010 |
A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Citrate (pro-S)- | 2010 |
RGD modified albumin nanospheres for tumour vasculature targeting.
Topics: Animals; Antimetabolites, Antineoplastic; Cattle; Cells, Cultured; Drug Carriers; Drug Delivery Syst | 2011 |
A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo.
Topics: Amino Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase | 2013 |
5-Fluorouracil-cisplatin adducts with potential antitumor activity.
Topics: Animals; Antineoplastic Agents; Cisplatin; Drug Screening Assays, Antitumor; Fluorouracil; Magnetic | 2003 |
HYPERBARIC OXYGEN AND 5-FLUOROURACIL IN THE TREATMENT OF EXPERIMENTAL MELANOMA.
Topics: Animals; Fluorouracil; Hyperbaric Oxygenation; Melanoma; Melanoma, Experimental; Mice; Neoplasms; Ne | 1964 |
Potential therapeutic applications of recombinant, invasive E. coli.
Topics: Adhesins, Bacterial; Animals; Antineoplastic Agents; Bacterial Proteins; Caco-2 Cells; Cell Line; De | 2004 |
Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Transformation, Neoplastic; Down-Regulation; Female; | 2004 |
A biologically active angiogenesis inhibitor, human serum albumin-TIMP-2 fusion protein, secreted from Saccharomyces cerevisiae.
Topics: Angiogenesis Inhibitors; Animals; Cells, Cultured; Endothelial Cells; Female; Fluorouracil; Gene Exp | 2007 |
Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Deliver | 2007 |
Silencing of endo-exonuclease expression sensitizes mouse B16F10 melanoma cells to DNA damaging agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Damage; E | 2007 |
Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.
Topics: Acitretin; Alitretinoin; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2008 |
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chromobacterium; Colonic Neoplasms; Dep | 1994 |
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chromobacterium; Colonic Neoplasms; Dep | 1994 |
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chromobacterium; Colonic Neoplasms; Dep | 1994 |
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Chromobacterium; Colonic Neoplasms; Dep | 1994 |
Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Drug Screening Assays, Antitumor; Fluorouracil; | 1996 |
Bromodeoxyuridine improves the cytotoxic effect of cisplatin: a comparison with 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Cisplatin; Drug Synergism; Fluorouracil; Male; Me | 1997 |
Therapeutic effects of 5-fluorouracil microspheres on peritoneal carcinomatosis induced by Colon 26 or B-16 melanoma in mice.
Topics: Animals; Biocompatible Materials; Colonic Neoplasms; Fluorouracil; Injections, Intraperitoneal; Lact | 1998 |
Microdialysis assessment of 5-fluorouracil release from thermosensitive magnetoliposomes induced by an electromagnetic field in tumor-bearing mice.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Carriers; Electromagnetic Fields; Female; Fluorouraci | 1998 |
Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Moda | 1997 |
Nitric oxide-mediated regulation of chemosensitivity in cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell | 2001 |
5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole.
Topics: Animals; Combined Modality Therapy; Dipyridamole; Drug Screening Assays, Antitumor; Drug Synergism; | 1992 |
Effect of subconjunctivally administered antineoplastics on experimentally induced intraocular malignant tumour.
Topics: Animals; Antineoplastic Agents; Conjunctiva; Cytarabine; Female; Fluorouracil; Injections; Iris Neop | 1989 |
Carcinogenesis and aging. VIII. Effect of host age on tumour growth, metastatic potential, and chemotherapeutic sensitivity to 1.4-benzoquinone-guanylhydrazonethiosemicarbazone (ambazone) and 5-fluorouracil in mice and rats.
Topics: Adenocarcinoma; Aging; Animals; Antineoplastic Agents; Cell Division; Female; Fluorouracil; Leukemia | 1988 |
Fluorouracil therapy of intraocular Greene melanoma in the rabbit.
Topics: Animals; Eye Neoplasms; Fluorouracil; Melanoma, Experimental; Rabbits | 1988 |
Verapamil enhances antitumor activity without increasing myeloid toxicity.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Drug Synergism; Drug Therapy, Combination; Female; Fluo | 1987 |
[Antimetastatic properties of aloe juice].
Topics: Aloe; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cyc | 1986 |